Oncology Venture presents LiPlaCis on AACR in New Orleans

Hoersholm, Denmark; March 4th, 2016 – Oncology Venture Sweden AB (OV:ST) announces that data from phase 1 dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis in patients with advanced refractory tumors will be presented 16-20 of April at the AACR (American Association for Cancer Research) Annual Meeting 2016 in New Orleans. It is expected to be attended by more than 19500 professionals, scientists, doctors, patients, and students from all over the world.

“I look very much forward to have these data from the pharmacodynamic part of the Phase 1 study presented and discussed. The study compares the level of LiPlaCis delivered in the tumor to than in normal tissue. The LiPlaCis targeted therapy is expected to be more efficient than the conventional cisplatin treatment,” Said Adjunct professor Peter Buhl Jensen, M.D., CEO of Oncology Venture.

The Phase 1 study to evaluate the safety and tolerability of LiPlaCis in patients with advanced tumours is running at a Phase 1 Unit at a University Hospital in Copenhagen and has included 18 patients in the dose escalation part of a phase 1 study in solid tumors. The LiPlaCis program is now on the verge of moving into the extension phase 2 designed trial (part of the phase 1 application where patients with a specific disease – here metastatic breast cancer - are included to investigate early Proof of Concept – i.e. effect of the drug. LiPlaCis™ is administered intravenously in cycles weekly on day 1, day 8 Upon the investigator’s judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.

Conference details:

**Session Title:** Phase I Clinical Trials 2  
**Session Date and Time:** Wednesday Apr 20, 2016 8:00 AM - 12:00 PM  
**Session Location:** Convention Center, Halls G-J, Poster Section 13  
**Poster Board Number:** 15  
**Permanent Abstract Number:** CT154

About LiPlaCis

Cisplatin is one of the most widely used drugs in the treatment of cancer due to its documented efficacy in a number of tumour types. Cisplatin is used in the treatment of large indications as lung cancer EU+US ≈ 480,000 new cases annually), head and neck cancer (500,000 cases annually worldwide) bladder cancer (EU+US ≈ 170,000 annually) and ovarian cancer (EU+US = 71,000 annually). The lipid formulation from LiPlasome is the answer to a well-established need for improving cisplatin therapy and improving the formulation of the drug, so that a more selective up-take of cisplatin administered takes place at the tumour sites. LiPlasome Pharma ApS has identified and incorporated a mechanism into their liposomes - called LiPlasomes - designed to trigger the release of an encapsulated drug specifically in the tumour tissue. An enzyme especially present on tumors called secretory phospholipase A2 (sPLA2), is utilised to break down the LiPlaCis once it has accumulated in the cancer tissue. The lipid composition of the LiPlasomes is tailored to be specifically sensitive to degradation by the sPLA2 enzyme and thereby for release of the encapsulated drug. The technology behind LiPlaCis™ was originally developed by scientists from Danish Technical University -DTU.

About the Drug Response Predictor -DRP™ - screening tool
Oncology Venture uses the MPI DRP™ to select those patients that by the gene signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased.

This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ based on microRNA is used on certain products where the DRP™ based on messenger RNA is more broadly useable and more validated.

**About the Drug Response Predictor (DRP™) screening tool**

This method builds on the comparison of sensitive and resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network.

**For further information, please contact**

Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

---

**About Oncology Venture Sweden AB**

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.